The Angular Clustering of Galaxy Pairs

We identify close pairs of galaxies from 278 deg^2 of Sloan Digital Sky Survey commissioning imaging data. The pairs are drawn from a sample of 330,041 galaxies with 18 < r^* < 20. We determine the angular correlation function of galaxy pairs, and find it to be stronger than the correlation function of single galaxies by a factor of 2.9 +/- 0.4. The two correlation functions have the same logarithmic slope of 0.77. We invert Limber's equation to estimate the three-dimensional correlation functions; we find clustering lengths of r_0= 4.2 +/- 0.4 h^{-1} Mpc for galaxies and 7.8 +/- 0.7 h^{-1} Mpc for galaxy pairs. These results agree well with the global richness dependence of the correlation functions of galaxy systems.Comment: 12 pages. ApJ, in pres

ESTUDIO COMPARATIVO DE SOFTWARE DE PLANEACIÓN ESTRATÉGICA DE SISTEMAS DE INFORMACIÓN

The strategic planning of information systems is a critical process in organizations that intend to maintain a constant level of innovation. This involves cognitive and organizational efforts that demand efficient and effective management of the information generated during this process. The basis for managing information lies in having a good computer system that allows retrieving information from multiple perspectives, associated with interests of different roles that are involved in the planning process. Based on these considerations, it is defined as the objective of this paper, to carry out a first version of a comparative study of software for the strategic planning of information systems, based on the identification of useful criteria by technological surveillance. With the monitoring, 13 criteria were identified. The selection decision constitutes a strategic decision to be considered by the organizations.&nbsp;La planeación estratégica de sistemas de información constituye un proceso de carácter crítico en las organizaciones que deseen mantener un nivel de innovación constante. Esta implica esfuerzos cognitivos y organizativos que demandan la gestión eficiente y eficaz de la información que se genera durante este proceso. La base para poder gestionar la información radica en tener un buen sistema informático que permita recuperar la información desde múltiples perspectivas, asociadas a intereses de diferentes roles que se involucran en el proceso de planeación. Basado en estas consideraciones, se define como objetivo del artículo, realizar una primera versión de estudio comparativo de software para la planeación estratégica de sistemas de información, a partir de la identificación de criterios de utilidad por la vigilancia tecnológica. Con la vigilancia se identificaron 13 criterios. La decisión de selección constituye una decisión estratégica a considerar por parte de las organizaciones.&nbsp

A Magellan M2FS Spectroscopic Survey of Galaxies at 5.5<z<6.8: Program Overview and a Sample of the Brightest Lyman-alpha Emitters

We present a spectroscopic survey of high-redshift, luminous galaxies over four square degrees on the sky, aiming to build a large and homogeneous sample of Ly$\alpha$ emitters (LAEs) at $z\approx5.7$ and 6.5, and Lyman-break galaxies (LBGs) at $5.5<z<6.8$. The fields that we choose to observe are well-studied, such as SXDS and COSMOS. They have deep optical imaging data in a series of broad and narrow bands, allowing efficient selection of galaxy candidates. Spectroscopic observations are being carried out using the multi-object spectrograph M2FS on the Magellan Clay telescope. M2FS is efficient to identify high-redshift galaxies, owing to its 256 optical fibers deployed over a circular field-of-view 30 arcmin in diameter. We have observed $\sim2.5$ square degrees. When the program is completed, we expect to identify more than 400 bright LAEs at $z\approx5.7$ and 6.5, and a substantial number of LBGs at $z\ge6$. This unique sample will be used to study a variety of galaxy properties and to search for large protoclusters. Furthermore, the statistical properties of these galaxies will be used to probe cosmic reionization. We describe the motivation, program design, target selection, and M2FS observations. We also outline our science goals, and present a sample of the brightest LAEs at $z\approx5.7$ and 6.5. This sample contains 32 LAEs with Ly$\alpha$ luminosities higher than 10$^{43}$ erg s$^{-1}$. A few of them reach $\ge3\times10^{43}$ erg s$^{-1}$, comparable to the two most luminous LAEs known at $z\ge6$, `CR7' and `COLA1'. These LAEs provide ideal targets to study extreme galaxies in the distant universe.Comment: 18 pages, 11 figures, Accepted for publication in The Astrophysical Journa

Rekayasa Model Sistem Informasi Web Sertifikasi Kompetensi Di Lembaga Sertifikasi Profesi Menggunakan Metodologi Modeldriven Uwe (Uml-based Web Engineering)

Tenaga kerja Indonesia yang kompeten semakin penting menjelang pelaksanaan Asean Economic Community (AEC) pada tahun 2015. Pemerintah memastikan kompetensi tenaga kerja melalui program sertifikasi kompetensi yang dilaksanakan oleh Lembaga Sertifikasi Profesi (LSP) yang ditunjuk oleh BNSP (Badan Nasional Sertifikasi Profesi). LSP bertanggung jawab terhadap pengembangan standar kompetensi, sertifikasi kompetensi, dan pelaksana akreditasi Tempat Uji Kompetensi (TUK). Sistem manajemen berteknologi informasi diperlukan untuk mendukung operasional LSP agar efisien, cepat, dan produktif. Sistem web telah menjadi salah satu platform yang paling sering digunakan sebagai basis suatu sistem. Pendekatan pengembangan model-driven diyakini paling tepat untuk rekayasa web. Metode pendekatan sistem yang digunakan yaitu UWE (UML-Based Web Engineering) karena kompatibilitasnya dengan alat UML yang sudah akrab di kalangan pengembang sistem dan mencakup seluruh siklus pengembangan. Penelitian ini menghasilkan suatu alternatif model sistem manajemen sertifikasi kompetensi dan lisensi LSP yang dengan pendekatan model-driven rancangan sistem bersifat flesibel sehingga relatif mudah penerapannya diberbagai LSP yang meskipun sebagian besar struktur dan prosedur sertifikasinya sama tetapi tetap ada keunikan di masing-masing LSP. Data penelitian diperoleh dari sejumlah LSP, asesor, asesi, dan TUK

Factors Affecting the Pharmacokinetics and Pharmacodynamics of PEGylated Liposomal Irinotecan (IHL-305) in Patients with Advanced Solid Tumors

IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors associated with interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 in patients with advanced solid tumors. IHL-305 was administered intravenously once every 4 weeks as part of a Phase I study. Pharmacokinetic studies of the liposomal sum total CPT-11, released CPT-11, SN-38, SN-38G, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, and 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin in plasma were performed. Noncompartmental and compartmental pharmacokinetic analyses were conducted using pharmacokinetic data for sum total CPT-11. The pharmacokinetic variability of IHL-305 is associated with linear and nonlinear clearance. Patients whose age and body composition (ratio of total body weight to ideal body weight [TBW/IBW]) were greater than the median age and TBW/IBW of the study had a 1.7-fold to 2.6-fold higher ratio of released CPT-11 area under the concentration versus time curve (AUC) to sum total CPT-11 AUC. Patients aged \u3c60 years had a 1.3-fold higher ratio of percent decrease in monocytes at nadir to percent decrease in absolute neutrophil count at nadir as compared with patients aged ≥60 years. There was an inverse relationship between patient age and percent decrease in monocytes at nadir, ie, younger patients have a higher percent decrease in monocytes. Patients with a higher percent decrease in monocytes at nadir have a decreased plasma exposure of sum total CPT-11. The pharmacokinetics and pharmacodynamics of IHL-305 are consistent with those of other PEGylated liposomal carriers. Interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 was associated with age, body composition, and monocytes

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5% of tumor cells. Results Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.

BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. METHODS: MEDI0680 was administered intravenously once every 2 weeks (Q2W) or once every 3 weeks at 0.1, 0.5, 2.5, 10 or 20 mg/kg. Two cohorts received 20 mg/kg once a week for 2 or 4 weeks, then 20 mg/kg Q2W. All were treated for 12 months or until progression. The primary endpoint was safety. Secondary endpoints were efficacy and pharmacokinetics. Exploratory endpoints included pharmacodynamics. RESULTS: Fifty-eight patients were treated. Median age was 62.5 years and 81% were male. Most had kidney cancer (n = 36) or melanoma (n = 9). There were no dose-limiting toxicities. Treatment-related adverse events occurred in 83% and were grade ≥ 3 in 21%. Objective clinical responses occurred in 8/58 patients (14%): 5 with kidney cancer, including 1 with a complete response, and 3 with melanoma. The relationship between dose and serum levels was predictable and linear, with apparent receptor saturation at 10 mg/kg Q2W and all 20 mg/kg cohorts. CONCLUSIONS: MEDI0680 induced peripheral T-cell proliferation and increased plasma IFNγ and associated chemokines regardless of clinical response. CD8+ T-cell tumor infiltration and tumoral gene expression of IFNG, CD8A, CXCL9, and granzyme K (GZMK) were also increased following MEDI0680 administration. TRIAL REGISTRATION: NCT02013804 ; date of registration December 12, 2013

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). We report ≥2-year follow-up data for avelumab treatment and exploratory subgroup analyses in patients with urothelial carcinoma. METHODS: Patients with previously treated advanced/metastatic urothelial carcinoma, pooled from two cohorts of the phase Ib JAVELIN Solid Tumor trial, received avelumab 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity or withdrawal. End points included best overall response and progression-free survival (PFS) per RECIST V.1.1, overall survival (OS) and safety. Post hoc analyses included objective response rates (ORRs) in subgroups defined by established high-risk/poor-prognosis characteristics and association between time to response and outcome. RESULTS: 249 patients received avelumab; efficacy was assessed in 242 postplatinum patients. Median follow-up was 31.9 months (range 24-43), and median treatment duration was 2.8 months (range 0.5-42.8). The confirmed ORR was 16.5% (95% CI 12.1% to 21.8%; complete response in 4.1% and partial response in 12.4%). Median duration of response was 20.5 months (95% CI 9.7 months to not estimable). Median PFS was 1.6 months (95% CI 1.4 to 2.7 months) and the 12-month PFS rate was 16.8% (95% CI 11.9% to 22.4%). Median OS was 7.0 months (95% CI 5.9 to 8.5 months) and the 24-month OS rate was 20.1% (95% CI 15.2% to 25.4%). In post hoc exploratory analyses, avelumab showed antitumor activity in high-risk subgroups, including elderly patients and those with renal insufficiency or upper tract disease; ORRs were numerically lower in patients with liver metastases or low albumin levels. Objective response achieved by 3 months versus later was associated with longer OS (median not reached (95% CI 18.9 months to not estimable) vs 7.1 months (95% CI 5.2 to 9.0 months)). Safety findings were consistent with previously reported 6-month analyses. CONCLUSIONS: After ≥2 years of follow-up, avelumab showed prolonged efficacy and acceptable safety in patients with platinum-treated advanced/metastatic urothelial carcinoma, including high-risk subgroups. Survival appeared longer in patients who responded within 3 months. Long-term safety findings were consistent with earlier reports with avelumab treatment in this patient population

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Aurora A kinase is critical in assembly and function of the mitotic spindle. It is overexpressed in various tumor types and implicated in oncogenesis and tumor progression. This trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of MLN8054, a selective small-molecule inhibitor of Aurora A kinase